Pharmaceutical Headlines promotes the development of oral antibiotics and Pfizer's acquisition of Arixa Pharmaceuticals.

(2020/10/23) Pharmaceutical representatives on the "high-pressure line" are transformed or eliminated; cancer-targeted therapy research and development and trading "front wave" "unexpictured" after wave" hit again; Q3 U.S. venture capital financing in 2020 announces new trends in the pharmaceutical health sector; whether gene therapy in the $10 billion haemophilia market can be successfully broken... (Click on the title to get the original article) Pfizer will acquire Arixa Pharmaceuticals to advance the development of oral antibiotics yesterday (October 22), dedicated to the development of the next generation of oral antibiotics for drug-resistant Gloria negative bacterial infection arixa Pharmaceuticals announced that Pfizer's hospital business has now agreed to acquire Arixa.
the financial terms of the acquisition have not been disclosed.
: Pfizer is the ideal company to include THEX-1796 in subsequent clinical trials.
the "arterial network" stepped on the "high-pressure line" of the pharmaceutical representative was transformed or died? In recent years, with the continuous development and deepening of medical reform, the discussion on the future development path of medical representatives has repeatedly been hotly searched.
eve of the National Day holiday, on September 30, the State Drug Administration officially issued the Measures for the Administration of the Filing of Pharmaceutical Representatives (Trial).
: The reputation of pharmaceutical representatives has not been very good.
New Kangjie Cancer Targeted Therapy Research and Development and Trading "Front Wave" "Front Wave" Followed By August 2017, Novartis' Cytogenetic Therapy Kymriah, which targets CD19, was approved by the FDA to treat acute lymphoblastic leukemia in B-cell prescells, becoming the first CAR personalized-T therapy to be made from patients' autoimmune cells.
followed suit, Kite Pharma's Yescarta was approved by the FDA in October 2017 to treat relapsed or incurable large B-cell lymphoma, which led Gilead to buy the company for $12 billion.
approval of the two therapies and related deals have sparked enthusiasm for investing in countless start-ups working in cell and gene therapy (CGT).
: What is driving the rapid development of cancer-targeted therapies? Q3 U.S. venture capital financing in 2020 announces what are the new trends in the pharmaceutical health sector? CB Insights and PwC recently released MoneyTree Report for Q3 2020, which provides an inventory and analysis of funding for VC and startups in the third quarter of 2020. Headline: Active financing in the pharmaceutical and health sectors.
can gene therapy break through the $10 billion hemophilia market? For Ryan Hallock, he can't have much physical movement, or even fall on his wrong arm or walk, and he bleeds.
, Hallock used drugs to help stop the bleeding, but it didn't take long for the drugs to be useless to him.
, he started experimenting with new experimental gene therapies, and so far he hasn't had any bleeding.
the headline bacteria: "Healing" may be a step closer.
.